

1
2
3
4 **JNS-D-19-00244 - Research Paper - Journal of Neurological Sciences**

5
6
7 **Lack of independent mood-enhancing effect for dopaminergic medications in early**

8
9 **Parkinson disease**

10 Alberto J. Espay, MD, MSc;¹ Eric D. Foster, PhD;² Christopher S. Coffey, PhD;² Liz Uribe,
11 MS;² Chelsea J. Caspell-Garcia, MS;² Daniel Weintraub, MD³⁻⁵, and the Parkinson's Progression
12 Markers Initiative*

- 13
14
15
16
17
18
19
20
21 1. James J and Joan A Gardner Family Center for Parkinson's Disease and Movement
22 Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
23
24
25
26
27 2. Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA
28
29
30 3. Department of Neurology, Perelman School of Medicine at the University of
31 Pennsylvania, Philadelphia, PA
32
33
34 4. Department of Psychiatry, Perelman School of Medicine at the University of
35 Pennsylvania, Philadelphia, PA
36
37
38
39 5. Department of Veterans Affairs, Philadelphia VA Medical Center, Philadelphia, PA
40
41

42
43 Word count: 2,116; Abstract word count: 214; Title character count (with spaces): 96; Tables: 3;

44
45 Figures: 1; References: 24; Supplemental material (Supplementary Methods): 1
46
47

48 **All correspondence to:** Dr. Alberto J. Espay, University of Cincinnati Academic Health Center

49
50
51 260 Stetson St., Suite 2300, Cincinnati, OH 45267-0525, USA
52
53

54
55 P: 513-558-4035 - F: 513-558-7015 - E-mail: alberto.espay@uc.edu
56
57

58 ***Full list of authors can be found at <http://www.ppmi-info.org/>**
59
60
61
62
63
64
65

1
2
3
4 **ABSTRACT**
5
6

7 **Background:** A direct antidepressant effect has been reported for certain dopaminergic
8 medications used in the treatment of Parkinson disease (PD).
9

10 **Objective:** To examine whether dopaminergic medications may exert differential effects on
11 mood in early PD.
12

13 **Methods:** We analyzed prospectively-collected 5-year data on 405 early, drug-naïve (at
14 baseline) PD patients enrolled in the Parkinson’s Progression Markers Initiative (PPMI) cohort
15 study, initiated on levodopa, dopamine agonists (DAs), or monoamine-oxidase type B inhibitors
16 (iMAO-B) under naturalistic conditions. The outcome for depressive symptoms was the 15-item
17 Geriatric Depression Scale (GDS-15) score. Potential motor and cognitive confounders were
18 measured using the Unified Parkinson Disease Rating Scale (MDS-UPDRS-III) and the
19 Montreal Cognitive Assessment (MoCA). Three statistical models were used to determine
20 medication effects on GDS-15 scores: unadjusted, adjusted, and a marginal structural model.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Results:** One-third of patients in this cohort met GDS-15 threshold for clinically-significant
38 depressive symptoms ($GDS-15 \geq 5$). There was a marginal positive effect on GDS-15 scores after
39 iMAO-B treatment initiation (-0.35 95% CI: -0.73, 0.04; $p = 0.08$). There were no significant
40 interactions between any of the three medication groups, but robust interactions between MoCA
41 scores and both DAs ($p = 0.005$) and iMAO-B ($p = 0.03$) use on GDS-15 scores. Specifically, as
42 MoCA scores worsened, DAs yielded a steeper worsening of GDS-15 scores while iMAO-B a
43 moderating effect on GDS-15.
44
45
46
47
48
49
50
51
52

53 **Conclusion:** Dopaminergic medications have no direct effect on mood in early, unselected PD
54 patients.
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Keywords: Parkinson disease, mood, depression, dopamine agonists, levodopa, MAO-B
inhibitors

1
2
3
4 **1. INTRODUCTION**
5

6 Depression is a common comorbidity in Parkinson disease (PD), affecting approximately 30-
7
8 40% of patients [1]. The tricyclics amitriptyline, nortriptyline, and desipramine; selective
9
10 serotonin reuptake inhibitors citalopram, escitalopram, and paroxetine; and the serotonin-
11
12 norepinephrine reuptake inhibitor venlafaxine, may have antidepressant effects in PD [2-6].
13

14 Preliminary evidence suggests that there may also be a direct antidepressant effect by dopamine
15
16 agonists (DAs) [7-13] and monoamine oxidase type B inhibitors (iMAO-B) in PD [14,15]. These
17
18 observations have been from single-agent retrospective or placebo-controlled studies [13]. which
19
20 preclude a definitive answer to the question of whether putative antidepressant effects are unique
21
22 to a specific drug or drug class or typical of dopaminergic medications as a whole. Further, the
23
24 lack of comparisons across all dopaminergic medications, including levodopa, has made it
25
26 difficult to determine the extent to which mood enhancement may be explained by the
27
28 differential improvement in motor function that these drugs are known to exert. The latter is the
29
30 reason regulatory authorities consider PD-associated depression a “pseudospecific” therapeutic
31
32 target [16], which has hampered efforts at designing studies to properly examine the putative
33
34 mood-enhancing effects of DAs compared to other dopaminergic medications.
35
36
37
38
39
40
41
42
43
44

45 The primary objective of this study was to examine the effect on mood by different
46
47 dopaminergic drugs (levodopa, iMAO-B, and DAs) after correcting for their effects on motor
48
49 function, using the naturalistic treatment conditions of the longitudinal Parkinson Progression
50
51 Markers Initiative (PPMI) study cohort, whereby these drugs were administered to early,
52
53 treatment-naïve patients to target motor impairment rather than mood impairment.
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 **2. METHODS**
5

6
7 **2.1. Participants**
8

9 Patients with newly diagnosed, untreated PD were enrolled in the PPMI study, an observational,
10 international, multicenter (16 sites from the US, 5 from Europe, and 1 from Australia) study
11 designed to identify PD progression biomarkers. The aims and methodology of the study have
12 been published elsewhere [17]. The study was approved by the institutional review board at each
13 of the participating sites and written informed consent was obtained from all participants. At
14 completion of study baseline there were data from a total of 423 PD patients.
15
16
17
18
19
20
21
22
23
24
25

26 **2.2. Assessments**
27

28 PPMI participants underwent baseline and periodic assessments of motor and non-motor
29 features. Severity of depressive symptoms was assessed using the 15-item Geriatric Depression
30 Scale (GDS-15), a validated screening tool for depression in PD, with a cut-off score of ≥ 5
31 recommended to indicate the presence of clinically-significant depressive symptoms.[18]
32
33 Severity of state and trait anxiety symptoms was assessed with the State-Trait Anxiety Inventory
34 (STAI) [19]. Cognitive function was measured with the Montreal Cognitive Assessment (MoCA)
35 [20] and motor severity with the motor subscale of the Movement Disorders Society-Unified
36 Parkinson Disease Rating Scale (MDS-UPDRS-III) [21].
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **2.3. Treatment decisions by PPMI investigators**
51

52 Study participants could start dopaminergic treatment at any point after baseline at the judgment
53 of the investigators to address motor deficits. The cohort was not selected based on presence or
54 absence of depression. Information about medication dosages was not readily ascertained in the
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 database and is therefore not included. Search terms were used to identify each of the
5
6 commercially available antidepressant medications in the concomitant medications form.
7
8
9

10 11 **2.4. Statistical Analysis**

12
13 Traditional methods to estimate the effect of PD medications on GDS scores must control for the
14
15 presence of multiple confounders (e.g., MDS-UPDRS-III scores, MoCA scores, anti-depressant
16
17 use, STAI scores, and levodopa-equivalent daily doses) by including them as covariates in a
18
19 longitudinal model. However, these methods may not properly address the potential role of
20
21 confounding variables, particularly on a cohort not randomized according to the medications
22
23 examined, many of which may plausibly impact the use of other medications and affect GDS
24
25 scores as well as MDS-UPDRS-III and MoCA scores, which in turn may influence the decision-
26
27 making process by clinicians in choosing one medication over another.
28
29
30
31
32
33

34
35 We accessed the baseline and post-treatment Years 1 to 5 for GDS-15 and MDS-UPDRS-III data
36
37 divided by the three treatment-initiation groups of interest: levodopa, DAs (pramipexole,
38
39 ropinirole, and rotigotine), and iMAO-B (selegiline and rasagiline) as well as all possible
40
41 combination therapies involving the three groups. All groups may change each year; some
42
43 individuals can move from one group to another within a year. Between-group comparisons for
44
45 baseline age, gender, MoCA, GDS-15, STAI, and MDS-UPDRS-III variables were performed
46
47 using ANOVA for continuous variables and Chi-square tests for categorical variables. We
48
49 formulated three questions from the data: (1) is there a significant effect of either of the three
50
51 treatment groups on GDS scores? (2) are there any significant interactions among the treatments
52
53 on GDS scores? and (3) are there any significant interactions among the treatments and MDS-
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 UPDRS-III and MoCA scores on GDS scores? For each of these three questions, we used three
5
6 statistical models:

- 9 1. Unadjusted model. This model included baseline characteristics, PD medication use,
10 MDS-UPDRS-III scores, and MoCA scores.
- 11
12 2. Adjusted model. This model includes model 1, but also additional adjustments for
13
14 antidepressant use, STAI score, and levodopa equivalent daily dose (LEDD).
15
16
- 17
18 3. Marginal structural model (MSM). To robustly examine the effect of PD medications on
19
20 GDS scores given a complex web of relationships between the variables involved, we used
21
22 MSM, a causal model for the estimation of time-dependent exposure in the presence of time-
23
24 dependent confounders from observational data [22]. MSM account for the time-dependent
25
26 confounding through a re-balancing of the study population, as opposed to the traditional
27
28 approach of including these confounders directly in the statistical model. Implementing MSM
29
30 requires developing a weight for each participant in the dataset. If a weight is <1 (but >0), that
31
32 particular participant is down-weighted (given less influence than one person-unit). If a weight
33
34 is >1 , that particular participant is up-weighted (given more influence than one person-unit). In
35
36 this manner, the entire study population is rebalanced across important time-varying confounders
37
38 among medications, MDS-UPDRS-III scores, MoCA scores, antidepressant use, STAI score, and
39
40 LEDD, and direct inference of the medications on GDS scores can be made (see further details in
41
42 Supplementary Methods, online).
43
44
45
46
47
48
49
50
51
52

53 **3. RESULTS**

54
55 Of the 423 PPMI PD subjects, 368 provided at least one complete baseline record and one
56
57 complete follow-up record. Of the 329 subjects with Year 1 data, 169 (51.4%) were not on
58
59
60
61
62
63
64
65

1
2
3
4 medication by the end of Year 1; 63 of 279 (22.6%) remained untreated by the end of Year 2;
5
6 only 30 of 250 (12.0%) by the end of Year 3; and only 15 of 209 (7.2%) by the end of Year 5
7
8 (Figure 1). As expected, over the course of the study period, monotherapy for DAs and MAO-B
9
10 inhibitors became less common, in favor of levodopa monotherapy and combination therapy.
11
12
13
14
15

16 **3.1. Demographics and Assessments at Baseline.**

17
18 Because all PPMI subjects were untreated at baseline, we group subjects' baseline characteristics
19
20 by their treatments recorded at Year 1. Patients on levodopa were older (mean age, 64.7 ± 10.3
21
22 years) and had greater motor severity (MDS-UPDRS-III, 25.5 ± 9.2) compared to those on DAs
23
24 or iMAO-B (Table 1), consistent with recommendations to initiate levodopa in elderly and more
25
26 impaired patients.
27
28
29
30
31
32

33
34 There were 121 patients treated with antidepressants throughout the study period, of which 112
35
36 (30.4% of the entire cohort) met criteria for clinically-significant depressive symptoms at any
37
38 time during their follow-up ($GDS-15 \geq 5$). Because of the significant differences across groups
39
40 for age and MDS-UPDRS-III variables, we then investigated all pairwise differences to evaluate
41
42 the sources of the overall difference. As all pairwise comparisons among the medication groups
43
44 that were associated with a significant p-value for either the age or MDS-UPDRS-III variables
45
46 involved the levodopa monotherapy group, we conclude that only levodopa drove the significant
47
48 differences observed in Table 1. Gender, cognitive function, STAI, and GDS-15 were similar
49
50 across all groups at baseline.
51
52
53
54
55
56

57 **3.2. Effect of medications on GDS scores.**

1
2
3
4 There was a consistent trend in GDS-15 improvement for subjects on iMAO-B versus those not
5 on iMAO-B (per MSM model: -0.35 95%; CI: -0.73, 0.04; p = 0.08). None of the estimates for
6 this or other medication groups were, however, statistically significantly different from zero on
7 any of the statistical models (Table 2).
8
9
10
11
12
13
14
15

16 **3.3. Interactions among medications on GDS scores.**

17
18 There were no significant interactions among the medications in any of the statistical models (all
19 p > 0.05). There was no evidence that any of the combination therapies were associated with
20 significant changes in GDS scores.
21
22
23
24
25
26
27
28

29 **3.4. Interactions among medications and MDS-UPDRS-III and MOCA scores on GDS** 30 **scores.**

31
32 After removing the non-statistically significant interactions, three interactions were either
33 statistically significant or marginally non-statistically significant in all three statistical models
34 (Table 3). There were strong interactions between MoCA scores and both DAs (p = 0.005) and
35 iMAO-B (p = 0.03) on GDS-15 scores. Worsening MoCA scores for those on DAs were
36 associated with a larger worsening of GDS-15 scores (total effect of $-0.03 + 0.15 = 0.12$ GDS-15
37 point increase per MoCA point decrease) while iMAO-B had a moderating effect (total effect of
38 $-0.03 + -0.12 = -0.15 = 0.15$ GDS-15 point decrease per MoCA point decrease). Using the
39 stringent MSM modeling approach, the interaction between MDS-UPDRS-III scores and iMAO-
40 B became marginally non-statistically significant although the effect still pointed in the direction
41 of iMAO-B as a moderator of the effect of changes in MDS-UPDRS-III scores on GDS-15
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 scores (total effect of $0.04 + -0.03 = 0.01$ GDS-15 point increase per MDS-UPDRS-III point
5
6 increase).
7
8
9

10 11 **4. DISCUSSION** 12 13

14 In this unselected cohort of early PD patients with one-third meeting GDS-15-threshold for
15
16 depression and followed for 5 years, we found that dopaminergic medications had not effect on
17
18 mood, as measured by GDS-15. While there was a positive mood trend by iMAO-B, the
19
20 differences were not statistically significant for any of the medication groups. Thus, these data
21
22 suggest that changes in the severity of depressive symptoms in PD may be driven by non-
23
24 dopaminergic mechanisms and any mood stabilization may not be explained by the differential
25
26 improvement in motor function that dopaminergic therapies are known to exert. This finding
27
28 does not exclude the possibility that there may be an antidepressant effect in those with severe
29
30 depression, a population insufficiently represented in this cohort.
31
32
33
34
35
36
37

38 Of interest, we found that cognitive function affected the relationship between medication effect
39
40 and mood: as MoCA scores worsened, DAs yielded a steeper worsening of GDS-15 scores
41
42 compared to those not on DAs. Conversely, iMAO-B use led to a moderating or mood stabilizing
43
44 effect in the setting of worsening MoCA scores.
45
46
47
48
49

50 Our study does not support prior evidence of a mood enhancing effect by iMAO-B in PD
51
52 [14,15], presumably independent from motor improvement [15], which was shown as not
53
54 sustained over time in one study [23]. The data argue against the potential for direct
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 antidepressant effects previously suggested for pramipexole [13]. All dopaminergic medications
5
6 were associated with GDS-15 worsening, in parallel with motor decline.
7
8
9

10
11 Some important limitations in our study should be highlighted, largely related to the prospective
12
13 observational nature of PPMI. The PPMI cohort was treated under naturalistic conditions,
14
15 creating natural biases in the allocation of medications, such as levodopa initiated more common
16
17 in older patients with worse motor severity, which required adjusting for age and motor severity
18
19 in the statistical models. In addition, given that patients were not preselected for presence of
20
21 depression at baseline, there was a floor effect for GDS-15 scores: the mean baseline score was
22
23 ≤ 3.0 for all groups, limiting the range of change for any dopaminergic treatment. Also, these
24
25 scores are sub-threshold for depression (GDS-15 cutoff of 5 is required for optimal sensitivity
26
27 71.8% and specificity 78.2% for the diagnosis of depression using the Structured Clinical
28
29 Interview for DSM-IV [SCID] as gold standard) [24]. Thus, we could not refer to an
30
31 “antidepressant” effect for any of the drugs examined, but rather as changes in the severity of
32
33 depression symptoms. Mean changes from baseline in GDS-15 were small (-0.24 (2.28 SD) at
34
35 Year 1, -0.11 (2.75 SD) at Year 2, -0.14 (2.71 SD) at Year 3, -0.02 (2.87 SD) at Year 4, and 0.14
36
37 (3.08 SD) at Year 5). This difference is further diluted given the high variability in the cohorts,
38
39 the relatively low sample size after dividing the treated PD subjects into seven non-overlapping
40
41 medication groups, and the reduction in monotherapy-treated patients (as it would be expected in
42
43 naturalistic conditions) toward Year 5. Finally, there were no motor differences across
44
45 dopaminergic treatments, which suggest levodopa-treated patients may have been relatively
46
47 undertreated. The levodopa-treated cohort had a change comparable to DAs and iMAO-B (10.8
48
49 MDS-UPDRS-III points in levodopa versus 10.1 and 12.8 in DAs and iMAO-B, respectively).
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 This prevented answering the question of whether a more robust motor improvement, as it may
5
6 be expected in optimized levodopa-treated patients, might have induced mood-enhancing effects.
7
8

9
10
11 In conclusion, these data suggest a correlation between depressive symptoms and severity of
12
13 motor function but reject an independent effect on mood by any class of dopaminergic
14
15 medications in a cohort of unselected early PD patients treated under naturalistic conditions. A
16
17 dedicated prospective study in a large PD population selected for baseline depression but equally
18
19 optimized for motor function will be required to answer whether any mood-enhancing effect may
20
21 be revealed by iMAO-B compared with other medications in depressed PD patients, as
22
23 tentatively suggested in this analysis.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Compliance with ethical standards

Conflicts of interest: All authors declare that they have no competing interest. Other financial information unrelated to the current research covering the past year is documented at the end of the manuscript.

Ethical standards statement: This research study has been conducted in agreement with international ethical standards for medical research involving human participants, in line with the Declaration of Helsinki.

Funding: We acknowledge the support of the Michael J. Fox Foundation for Parkinson’s disease.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure legend

Figure 1. Proportion of PPMI subjects in each medication group over time. Created from data extracted on May 7, 2018.

1
2
3
4 **Financial disclosure for the previous 24 months:**
5

6
7 **Dr. Espay** has received grant support from the NIH, Great Lakes Neurotechnologies and the
8 Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board
9 member for Abbvie, Adamas, Acadia, Acorda, Neuroderm, TEVA, Impax, Sunovion, Lundbeck,
10 Osmotica Pharmaceutical, and USWorldMeds; publishing royalties from Lippincott Williams &
11 Wilkins, Cambridge University Press, and Springer; and honoraria from Abbvie, UCB,
12 USWorldMeds, Lundbeck, Acadia, Sunovion, the American Academy of Neurology, and the
13 Movement Disorders Society.
14

15
16
17 **Dr. Foster** reports no disclosures.
18

19
20
21 **Dr. Coffey** reports no disclosures.
22

23
24
25 **Ms. Uribe** reports no disclosures.
26

27
28
29 **Ms. Caspell-Garcia** reports no disclosures.
30

31
32
33 **Dr. Weintraub** has received research funding or support from Michael J. Fox Foundation for
34 Parkinson's Research, National Institutes of Health (NINDS), Novartis Pharmaceuticals,
35 Department of Veterans Affairs, Avid Radiopharmaceuticals, Alzheimer's Disease Cooperative
36 Study, and the International Parkinson and Movement Disorder Society; honoraria from AbbVie,
37 Acadia, Biotie, Clintrex LLC, Janssen, Novartis, Pfizer, Teva Pharmaceuticals, UCB, and the
38 CHDI Foundation; license fee payments from the University of Pennsylvania for the QUIP and
39 QUIP-RS; royalties from Wolters Kluweland; and fees for legal consultation for lawsuit related
40 to antipsychotic prescribing in a patient with Parkinson's disease.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 **References**
5
6

7
8 1. Veazey C, Aki SO, Cook KF, Lai EC, Kunik ME (2005) Prevalence and treatment of
9 depression in Parkinson's disease. *J Neuropsychiatry Clin Neurosci* 17 (3):310-323.

10
11
12 doi:10.1176/appi.neuropsych.17.3.310
13
14

15
16
17 2. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K,
18 Shulman LM, Gronseth G, Weiner WJ, Quality Standards Subcommittee of the American
19 Academy of N (2006) Practice Parameter: evaluation and treatment of depression, psychosis, and
20 dementia in Parkinson disease (an evidence-based review): report of the Quality Standards
21 Subcommittee of the American Academy of Neurology. *Neurology* 66 (7):996-1002.
22
23
24
25
26
27
28

29 doi:10.1212/01.wnl.0000215428.46057.3d
30
31
32

33
34 3. Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, Destee A, Bordet
35 R, Defebvre L (2008) Comparison of desipramine and citalopram treatments for depression in
36 Parkinson's disease: a double-blind, randomized, placebo-controlled study. *Mov Disord* 23
37
38
39
40
41 (6):850-857. doi:10.1002/mds.21966
42
43
44

45
46 4. Weintraub D, Taraborelli D, Morales KH, Duda JE, Katz IR, Stern MB (2006)
47 Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. *J*
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

66
67 5. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A
68 (2009) A controlled trial of antidepressants in patients with Parkinson disease and depression.
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165

1
2
3
4 6. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA,
5
6 Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black
7
8 KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J,
9
10 Elmer L, Press D, Hyson HC, McDonald W, Group S-PS (2012) A randomized, double-blind,
11
12 placebo-controlled trial of antidepressants in Parkinson disease. *Neurology* 78 (16):1229-1236.
13
14 doi:10.1212/WNL.0b013e3182516244
15
16
17
18
19
20

21 7. Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, Zappia M,
22
23 Musch B, Depression/Parkinson Italian Study G (2006) Pramipexole versus sertraline in the
24
25 treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized
26
27 study. *J Neurol* 253 (5):601-607. doi:10.1007/s00415-006-0067-5
28
29
30
31
32

33 8. Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine
34
35 agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. *J*
36
37 *Neurol Sci* 248 (1-2):266-270. doi:10.1016/j.jns.2006.05.024
38
39
40
41

42 9. Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, Fanfrdlova Z, Fiedler J, Klajblova
43
44 H, Kulist'ak P, Ressner P, Svatova J, Urbanek K, Veliskova J (2003) Pramipexole and pergolide
45
46 in the treatment of depression in Parkinson's disease: a national multicentre prospective
47
48 randomized study. *Eur J Neurol* 10 (4):399-406
49
50
51
52

53 10. Czernecki V, Schupbach M, Yaici S, Levy R, Bardinet E, Yelnik J, Dubois B, Agid Y
54
55 (2008) Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive
56
57 symptom. *Mov Disord* 23 (7):964-969. doi:10.1002/mds.21949
58
59
60
61
62
63
64
65

1
2
3
4 11. Bertaina-Anglade V, La Rochelle CD, Scheller DK (2006) Antidepressant properties
5 of rotigotine in experimental models of depression. Eur J Pharmacol 548 (1-3):106-114.
6
7

8
9 doi:10.1016/j.ejphar.2006.07.022
10

11
12
13 12. Ray Chaudhuri K, Martinez-Martin P, Antonini A, Brown RG, Friedman JH, Onofrij
14 M, Surmann E, Ghys L, Trenkwalder C (2013) Rotigotine and specific non-motor symptoms of
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

doi:10.1016/j.parkreldis.2013.02.018

13. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E,
Weintraub D (2010) Pramipexole for the treatment of depressive symptoms in patients with
Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9
(6):573-580. doi:10.1016/S1474-4422(10)70106-X

14. Smith KM, Eyal E, Weintraub D, Investigators A (2015) Combined rasagiline and
antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms
and tolerability. JAMA Neurol 72 (1):88-95. doi:10.1001/jamaneurol.2014.2472

15. Korchounov A, Winter Y, Rossy W (2012) Combined beneficial effect of rasagiline
on motor function and depression in de novo PD. Clin Neuropharmacol 35 (3):121-124.

doi:10.1097/WNF.0b013e31823b1da8

16. Lebowitz BD (2004) Clinical trials in late life: new science in old paradigms.
Gerontologist 44 (4):452-458

1
2
3
4 17. Parkinson Progression Marker I (2011) The Parkinson Progression Marker Initiative
5
6 (PPMI). *Prog Neurobiol* 95 (4):629-635. doi:10.1016/j.pneurobio.2011.09.005
7
8

9
10
11 18. Weintraub D, Oehlberg KA, Katz IR, Stern MB (2006) Test characteristics of the 15-
12
13 item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. *Am J*
14
15 *Geriatr Psychiatry* 14 (2):169-175. doi:10.1097/01.JGP.0000192488.66049.4b
16
17
18

19
20
21 19. Spielberger CD, Gorsuch RL, Lushene RE (1970) Manual for the State Trait
22
23 Inventory. Consulting Psychologists Press, Palo Alto, CA
24
25

26
27 20. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I,
28
29 Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief
30
31 screening tool for mild cognitive impairment. *J Am Geriatr Soc* 53 (4):695-699.
32
33
34
35 doi:10.1111/j.1532-5415.2005.53221.x
36
37

38
39 21. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe
40
41 W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE,
42
43 Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van
44
45 Hilten JJ, LaPelle N, Movement Disorder Society URTF (2008) Movement Disorder Society-
46
47 sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale
48
49 presentation and clinimetric testing results. *Mov Disord* 23 (15):2129-2170.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

22. Robins JM, Hernan MA, Brumback B (2000) Marginal structural models and causal inference in epidemiology. *Epidemiology* 11 (5):550-560

23. Barone P, Santangelo G, Morgante L, Onofrj M, Meco G, Abbruzzese G, Bonuccelli U, Cossu G, Pezzoli G, Stanzione P, Lopiano L, Antonini A, Tinazzi M (2015) A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. *Eur J Neurol* 22 (8):1184-1191. doi:10.1111/ene.12724

24. Marc LG, Raue PJ, Bruce ML (2008) Screening performance of the 15-item geriatric depression scale in a diverse elderly home care population. *Am J Geriatr Psychiatry* 16 (11):914-921. doi:10.1097/JGP.0b013e318186bd67

Table 1. Baseline demographics and assessments stratified by medication treatment after one year of follow-up

		Not on Any	Monotherapy			Combination Therapy				Overall p-value
			L-dopa	DAs	iMAO-B	L-dopa + DAs	DA + iMAO-B	L-dopa + iMAO-B	All Three	
Age	Mean (SD)	61.4 (10.2)	64.2 (11.2)	59.8 (7.2)	58.5 (9.4)	66.1 (7.0)	60.1 (9.3)	60.5 (7.3)	60.2 (6.2)	0.226
Sex	N _{Male} (% _{Male})	106 (63%)	27 (75%)	17 (68%)	33 (72%)	4 (67%)	25 (68%)	4 (50%)	1 (50%)	0.787
MoCA	Mean (SD)	26.3 (2.7)	25.2 (3.4)	27.2 (2.3)	26.5 (2.9)	23.8 (2.7)	26.1 (2.8)	26.8 (3.0)	27.0 (1.4)	0.081
GDS-15	Mean (SD)	2.4 (2.6)	2.7 (2.3)	2.2 (3.1)	2.3 (2.7)	2.0 (1.7)	2.6 (3.1)	1.5 (0.5)	1.5 (2.1)	0.949
STAI	Mean (SD)	63.8 (18.8)	68.4 (18.8)	66.6 (20.6)	64.1 (18.3)	63.3 (12.4)	67.9 (20.8)	59.5 (6.5)	62.5 (20.5)	0.811
MDS-UPDRS-III	Mean (SD)	25.6 (10.4)	29.9 (11.5)	25.8 (12.6)	24.6 (10.8)	24.8 (14.2)	19.9 (10.4)	20.3 (9.3)	10.5 (0.7)	0.004

L-dopa: levodopa; iMAO-B: Monoamine oxidase type B inhibitors; DAs: dopamine agonists. MoCA: Montreal Cognitive Assessment; GDS-15: Geriatric Depression Scale; STAI: State-Trait Anxiety Inventory; MDS-UPDRS-III: motor subscale of the Movement Disorders Society-Unified Parkinson Disease Rating Scale.

Table 2. Effect of medication groups on depression scores (as per Geriatric Depression Scale)

Statistical Model	PD Medications								
	Levodopa			Dopamine agonists			MAO-B Inhibitors		
	Estimate (SE)	95% CI	p-value	Estimate (SE)	95% CI	p-value	Estimate (SE)	95% CI	p-value
Unadjusted	0.13 (0.16)	(-0.17, 0.44)	0.39	0.02 (0.17)	(-0.31, 0.35)	0.91	-0.29 (0.15)	(-0.59, 0.01)	0.06
Adjusted	0.08 (0.13)	(-0.17, 0.33)	0.54	-0.12 (0.13)	(-0.37, 0.13)	0.33	-0.21 (0.12)	(-0.44, 0.01)	0.07
MSM	0.13 (0.17)	(-0.21, 0.46)	0.46	-0.20 (0.19)	(-0.57, 0.17)	0.29	-0.35 (0.20)	(-0.73, 0.04)	0.08


Positive estimates mean worsening of mood as measured by the GDS-15 (Geriatric Depression Scale); negative estimates mean improvement. MSM: Marginal structural model.

Table 3. Interactions among medications and motor and cognitive scores on depression scores

Statistical Model	PD Medications								
	MDS-UPDRS-III x iMAO-B Use			MoCA x iMAO-B Use			MoCA x DAs Use		
	Estimate (SE)	95% CI	p-value	Estimate (SE)	95% CI	p-value	Estimate (SE)	95% CI	p-value
Unadjusted	-0.03 (0.01)	(-0.05, -0.01)	0.01	-0.09 (0.04)	(0.01, 0.17)	0.03	0.18 (0.06)	(-0.30, -0.06)	0.004
Adjusted	-0.01 (0.01)	(-0.03, 0.004)	0.11	-0.08 (0.03)	(0.01, 0.14)	0.03	0.13 (0.04)	(-0.22, -0.05)	0.002
MSM	-0.03 (0.02)	(-0.07, 0.004)	0.09	-0.12 (0.06)	(0.01, 0.23)	0.03	0.15 (0.05)	(-0.26, -0.05)	0.005

Positive estimates mean worsening of mood as measured by the GDS-15 (Geriatric Depression Scale); negative estimates mean improvement. Coefficients reflect the change in GDS-15 scores per unit of worsening in either the MDS-UPDRS-III or the MoCA scores. MSM: Marginal structural model. iMAO-B: Monoamine oxidase type B inhibitors; DAs: dopamine agonists. MoCA: Montreal Cognitive Assessment; MDS-UPDRS-III: motor subscale of the Movement Disorders Society-Unified Parkinson Disease Rating Scale.

Figure
[Click here to download high resolution image](#)



e-component

[Click here to download e-component: Supplementary Methods.docx](#)